Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating
-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed...
Stay updated with breaking news from Nasdaq Pcvx. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Topline Safety, Tolerability and Immunogenicity Data from VAX-31 Phase 1/2 Study (n=1,015) Expected in Third Quarter of 2024 -- -- VAX-31 is Designed...
Shares of Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) reached a new 52-week high during trading on Monday . The company traded as high as $66.48 and last traded at $66.41, with a volume of 180384 shares traded. The stock had previously closed at $64.31. Analyst Ratings Changes A number of analysts recently commented on […]
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report)’s share price hit a new 52-week high on Monday . The company traded as high as $66.48 and last traded at $66.41, with a volume of 180384 shares trading hands. The stock had previously closed at $64.31. Analyst Upgrades and Downgrades A number of brokerages recently weighed in […]
Vaxcyte, Inc. (NASDAQ:PCVX – Get Free Report) SVP Mikhail Eydelman sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $56.50, for a total value of $565,000.00. Following the transaction, the senior vice president now directly owns 21,035 shares in […]
Mizuho initiated coverage on shares of Vaxcyte (NASDAQ:PCVX – Free Report) in a report issued on Thursday, MarketBeat.com reports. The brokerage issued a buy rating and a $69.00 price target on the stock. Several other equities research analysts have also recently issued reports on the stock. Needham & Company LLC reissued a buy rating and […]